Quantoom & eTheRNA to collaborate on revolutionary RNA production system
pharmafile | June 29, 2021 | News story | Manufacturing and Production | RNA, collaboration
Quantoom and eTheRNA immunotherapies have announced a strategic collaboration to develop a revolutionary RNA production system (RPS) for both research and GMP-grade material.
The companies will work together to build an advanced, small footprint technology platform for the production of affordable RNA-based therapies, that can be used either within existing facilities or rapidly deployed to areas of urgent need.
The RPS will manufacture RNA small modular units, which can be shipped easily across multiple geographic regions. The RPS is intended to be scaled seamlessly from small scale preclinical batches to mass production of GMP-grade RNA. The only requirement will be for the RPS to be located inside a suitable clean room with an uninterrupted utility supply.
Bernard Sagaert, SVP Manufacturing and COO of eTheRNA, said: “Currently, the global supply of RNA is hampered by the lack of dedicated production facilities and by the cost of constructing new plants. The RPS will revolutionise the way RNA is produced and distributed globally and we are excited to be able to work with a leading developer and manufacturer like Quantoom to bring this vision to the market.”
Under the terms of the agreement, eTheRNA will transfer manufacturing technology to Quantoom with all materials and data necessary for the development of the novel RPS. Following completion of the RPS, Quantoom will be responsible for commercialisation of the system on a worldwide basis, with sales-related royalties payable to eTheRNA. International sales and distribution are expected to commence in 2023 following RPS production in Belgium.
José Castillo, CEO of Quantoom Biosciences, said: “We are delighted to enter into this collaboration agreement with eTheRNA, which has extensive experience in the field of RNA and like Quantoom, has a mission to change the RNA world.
“Through our combined knowhow, I am confident that Quantoom will be able to develop an open, integrated RNA platform that will enable manufacture of RNA-based vaccines and therapeutics at scale, resulting in affordable development and production of RNA-based drugs.”
Kat Jenkins
Related Content
EVerZom enters research and licensing agreement with GENFIT
EVerZom, a French biotech company developing exosome-based therapies for regenerative medicine, has entered into a …
Custom Pharmaceuticals launches new company for drug product development
Customs Pharmaceuticals, a full-service contract development and manufacturing organisation (CDMO), has launched Centrix Pharma Solutions, …
AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …
